Theragnostics announces that NephroScan, its radiodiagnostic imaging drug used as an aid for the evaluation of renal parenchymal disorders in adult and pediatric patients, including term neonates, has received Marketing Approval by the US Food and Drug Administration (FDA).
NephroScan, a proprietary kit for the preparation of technetium Tc 99m succimer injection, is Theragnostics
